Momenta Pharmaceuticals, Inc. (MNTA) SVP Sells $75,308.56 in Stock

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) SVP Bruce Leicher sold 4,948 shares of Momenta Pharmaceuticals stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $15.22, for a total transaction of $75,308.56. Following the completion of the sale, the senior vice president now owns 176,210 shares in the company, valued at $2,681,916.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Bruce Leicher also recently made the following trade(s):

  • On Monday, February 12th, Bruce Leicher sold 309 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $16.20, for a total transaction of $5,005.80.
  • On Thursday, February 8th, Bruce Leicher sold 1,861 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $16.00, for a total transaction of $29,776.00.
  • On Tuesday, November 21st, Bruce Leicher sold 803 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $13.15, for a total transaction of $10,559.45.

Momenta Pharmaceuticals, Inc. (NASDAQ MNTA) traded up $0.25 during mid-day trading on Wednesday, hitting $16.25. 934,334 shares of the company’s stock were exchanged, compared to its average volume of 927,496. Momenta Pharmaceuticals, Inc. has a one year low of $11.85 and a one year high of $19.46. The company has a market cap of $1,245.11, a P/E ratio of -20.31 and a beta of 1.80.

Several hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. raised its position in shares of Momenta Pharmaceuticals by 0.8% during the 4th quarter. BlackRock Inc. now owns 10,473,316 shares of the biotechnology company’s stock worth $146,105,000 after buying an additional 82,691 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Momenta Pharmaceuticals by 4.9% during the 2nd quarter. Vanguard Group Inc. now owns 6,243,767 shares of the biotechnology company’s stock worth $105,519,000 after buying an additional 290,090 shares in the last quarter. State Street Corp raised its position in shares of Momenta Pharmaceuticals by 8.1% during the 2nd quarter. State Street Corp now owns 2,653,427 shares of the biotechnology company’s stock worth $44,842,000 after buying an additional 197,978 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Momenta Pharmaceuticals by 9.3% during the 4th quarter. Renaissance Technologies LLC now owns 1,583,000 shares of the biotechnology company’s stock worth $22,083,000 after buying an additional 134,500 shares in the last quarter. Finally, Tocqueville Asset Management L.P. raised its position in shares of Momenta Pharmaceuticals by 243.6% during the 4th quarter. Tocqueville Asset Management L.P. now owns 963,784 shares of the biotechnology company’s stock worth $13,445,000 after buying an additional 683,296 shares in the last quarter. Institutional investors own 93.01% of the company’s stock.

Several brokerages recently weighed in on MNTA. Stifel Nicolaus reiterated a “hold” rating and issued a $18.00 price objective on shares of Momenta Pharmaceuticals in a research report on Tuesday, January 30th. BidaskClub upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday. Zacks Investment Research downgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, December 4th. Finally, Cowen set a $15.00 price objective on shares of Momenta Pharmaceuticals and gave the company a “hold” rating in a research report on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $15.30.

COPYRIGHT VIOLATION NOTICE: This news story was published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/14/momenta-pharmaceuticals-inc-mnta-svp-sells-75308-56-in-stock.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply